Genfit S A Revenue Growth Rates (GNFT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Genfit S a   (NASDAQ: GNFT)
 

GNFT's Revenue Growth by Quarter and Year

Genfit S A 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNFT Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 79.45
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 79.45

GNFTs Annual Revenue
Genfit S A 's Revenue in the fiscal year 2024 $ 79.45 millions
Genfit S A 's Revenue in the fiscal year 2023 $ 42.76 millions
Genfit S A 's Revenue in the fiscal year 2022 $ 29.75 millions
Genfit S A 's Revenue in the fiscal year 2021 $ 95.85 millions
Genfit S A 's Revenue in the fiscal year 2020 $ 8.69 millions




GNFT Revenue fourth quarter 2024 Y/Y Growth Comment
Genfit S a reported Revenue surge of 85.81% year on year in the fourth quarter 2024, to $ 79.45 millions, this is lower than Genfit S A 's recent average Revenue surge of 224.2%.

Looking into fourth quarter 2024 results within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Revenue growth. While Genfit S A ' s Revenue jump of 85.81% ranks overall at the positon no. 3719 in the fourth quarter 2024.


GNFT Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 85.81 % 43.73 % -68.96 % 1002.99 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   85.81 % 43.73 % -68.96 % -

Financial Statements
Genfit S A 's fourth quarter 2024 Revenue $ 79.45 millions GNFT's Income Statement
Genfit S A 's fourth quarter 2023 Revenue $ 42.76 millions Quarterly GNFT's Income Statement


GNFT Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   85.81 % 43.73 % -68.96 % -


Back to GNFT Growth rate Comparisons >> Back to GNFT Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #509
Overall #3719

Revenue Y/Y Growth Statistics
High Average Low
1003.11 % 224.2 % -81.06 %
(Dec 31 2021)   (Dec 31 2020)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #509
Overall #3719
Revenue Y/Y Growth Statistics
High Average Low
1003.11 % 224.2 % -81.06 %
(Dec 31 2021)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Genfit S A 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNFT's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNFT's IV. Quarter Q/Q Revenue Comment


Genfit S A 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 79.45 $ 42.76 $ 29.75 $ 95.85 $ 8.69
Y / Y Revenue Growth (TTM) 85.82 % 43.7 % -68.96 % 1003.11 % -81.06 %
Year on Year Revenue Growth Overall Ranking # 3719 # 3874 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 85.82 % 43.7 % -68.96 % 1003.11 % -81.06 %
Seq. Revenue Growth (TTM) Overall Ranking # 3719 # 2913 # 0 # 0 # 0


Cumulative Revenue growth Comment
Although Genfit S A 's Annual Revenue growth year on year were below company's average 224.2% , Revenue announced in the Dec 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 85.82% year on year, from 43.7% in Dec 31 2023.

In the Healthcare sector 508 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3719, from total ranking in previous quarter at 3874.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 51
Healthcare Sector # 509
Overall # 3719

Revenue TTM Y/Y Growth Statistics
High Average Low
1003.11 %
 224.2 %
-81.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 510
S&P 500 # 3719
Cumulative Revenue growth Comment
Although Genfit S A 's Annual Revenue growth year on year were below company's average 224.2% , Revenue announced in the Dec 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 85.82% year on year, from 43.7% in Dec 31 2023.

In the Healthcare sector 508 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3719, from total ranking in previous quarter at 3874.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 51
Healthcare Sector # 509
Overall # 3719

Revenue TTM Y/Y Growth Statistics
High Average Low
1003.11 %
224.2 %
-81.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 510
S&P 500 # 3719




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GNFT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2024
Tg Therapeutics Inc 146.04%$ 146.043 millions
Omniab Inc 124.06%$ 124.056 millions
Earth Science Tech Inc 117.75%$ 117.746 millions
Krystal Biotech Inc 116.26%$ 116.264 millions
Esperion Therapeutics Inc 114.30%$ 114.304 millions
Marker Therapeutics inc 113.13%$ 113.128 millions
Myomo Inc 111.46%$ 111.460 millions
Biorestorative Therapies Inc 106.19%$ 106.190 millions
Beyond Air Inc 100.77%$ 100.767 millions
Nuo Therapeutics Inc 100.43%$ 100.427 millions
First Choice Healthcare Solutions Inc 99.80%$ 99.800 millions
Scpharmaceuticals Inc 99.31%$ 99.311 millions
Qhslab Inc 98.71%$ 98.712 millions
Evoke Pharma Inc 97.40%$ 97.398 millions
Absci Corp96.75%$ 96.746 millions
Hims and Hers Health Inc 94.39%$ 94.395 millions
Dariohealth Corp 93.72%$ 93.718 millions
60 Degrees Pharmaceuticals Inc 92.20%$ 92.204 millions
Blueprint Medicines Corporation88.19%$ 88.190 millions
Ac Immune Sa88.19%$ 88.190 millions
Agilon Health Inc 86.69%$ 86.693 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Genfit S a 85.82%$ 85.821 millions
Harrow Inc 83.83%$ 83.829 millions
Zymeworks Inc 83.33%$ 83.333 millions
Orgenesis Inc 82.42%$ 82.424 millions
Macrogenics Inc 80.53%$ 80.532 millions
Septerna Inc 79.66%$ 79.661 millions
Avricore Health Inc 79.01%$ 79.014 millions
Ideaya Biosciences Inc 78.43%$ 78.435 millions


About Genfit S A Revenue Growth Rates (GNFT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Genfit S a (CIK 1757064).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001757064-25-000004
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Genfit S a ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.